**INSTRUCTIONS FOR USE**

- **Fig. 1** Turn right (clockwise) to break the seal and make a dispensing hole on the nozzle.
- **Fig. 2** Remove the ring and discard.
- **Fig. 3** Open the cap with turning left (anti-clockwise) and it is ready for use.
- **Fig. 4** Turn it up side down. Squeeze the walls of the bottle gently to deliver sterile drops into the eye.
- **Fig. 5** Replace the cap. Tighten it firmly and keep the bottle closed for subsequent use.
- **Fig. 6** Do not touch the nozzle.
- **Fig. 7** Do not rinse the nozzle.
- **Fig. 8** Do not expose to Sunlight.

**INDICATIONS**

- **BETAGA** is indicated for the control of intraocular pressure in chronic open angle glaucoma and ocular hypertension.

**CONTRAINICATIONS**

- **BETAGA** is contraindicated in patients with severe chronic obstructive pulmonary disease, bronchospasm, including bronchial asthma, and uncontrolled congestive heart failure. **BETAGA** is also contraindicated for those individuals who are hypersensitive to any component.

**PRECAUTIONS**

- General: **BETAGA** should be used with caution in patients with known contraindications to systemic use of beta- adrenergic receptor blocking agents. This includes abnormal low heart rate and heart block more severe than first degree. Congestive heart failure should be adequately controlled before beginning therapy with **BETAGA**. In patients with a history of significant cardiac disease, pulse rate should be monitored.

- **BETAGA** should be used with caution in patients with known hypersensitivity to other beta-adrenergic blocking agents. Use with caution in patients with known diminished pulmonary function. Drug interactions: **BETAGA** may have additive effects in patients taking systemic anti-hypertensive drugs. These possible additive effects may include: hypotension, bradycardia, dizziness, and/or syncope. Conversely, systemic beta- adrenergic blocking agents may potentiate the ocular hypotensive effect of **BETAGA**.

- Pregnancy: There are no adequate and well controlled studies in pregnant women. **BETAGA** should be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

- Nursing Mothers: It is not known whether this drug is secreted in human milk. Systemic beta blockers and topical Timolol Maleate are known to be secreted in human milk. Because similar drugs are secreted in human milk, caution should be exercised when **BETAGA** is administered to a nursing woman.

- Pediatric Use: Safety and effectiveness in children have not been established.

**ADVERSE REACTIONS**

- Blepharoconjunctivitis, transient ocular burning, stinging and decrease in heart rate blood pressure have been reported occasionally with the use of **BETAGA**. Urticaria has been reported rarely with the use of **BETAGA**. The following adverse effects have been reported rarely and discontinue the use with the use **BETAGA** has not been established. Change in heart rate, bradycardia, headache, dizziness, and blurred vision.

**DOSAGE AND ADMINISTRATION**

- The usual dose is once or twice a day.

**HOW SUPPLIED**

- **BETAGA** is available as sterile ophthalmic solution in 5 mL plastic dropper bottles.

**NOTE:** Store in a cool place. Protect from light. One prescription only.